A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors

被引：0
|
作者：
Schwartz, G. K.
Robertson, S.
Shen, A.
Wang, E.
Pace, L.
Dials, H.
Mendelson, D.
Shannon, P.
Gordon, M.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Exelixis Inc, San Francisco, CA USA
[3] Premier Oncol, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3513
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase I study of TP300 in patients (pts) with advanced solid tumors
    Anthoney, D. A.
    MacPherson, I.
    Twelves, C.
    Crawford, D.
    Siller, C.
    Nemat, S.
    Abe, M.
    Miwa, M.
    Evans, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
    Garland, LL
    Pegram, M
    Song, S
    Mendelson, D
    Parker, KE
    Martell, RE
    Gordon, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 229S - 229S
  • [43] Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
    Yap, Timothy A.
    Krebs, Matthew G.
    Postel-Vinay, Sophie
    El-Khouiery, Anthony
    Soria, Jean-Charles
    Lopez, Juanita
    Berges, Alienor
    Cheung, S. Y. Amy
    Irurzun-Arana, Itziar
    Goldwin, Andrew
    Felicetti, Brunella
    Jones, Gemma N.
    Lau, Alan
    Frewer, Paul
    Pierce, Andrew J.
    Clack, Glen
    Stephens, Christine
    Smith, Simon A.
    Dean, Emma
    Hollingsworth, Simon J.
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5213 - 5224
  • [44] Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
    Okamoto, Isamu
    Kaneda, Hiroyasu
    Satoh, Taroh
    Okamoto, Wataru
    Miyazaki, Masaki
    Morinaga, Ryotaro
    Ueda, Shinya
    Terashima, Masaaki
    Tsuya, Asuka
    Sarashina, Akiko
    Konishi, Koichi
    Arao, Tokuzo
    Nishio, Kazuto
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2825 - 2833
  • [45] Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
    Macarulla, Teresa
    Cervantes, Andres
    Elez, Elena
    Rodriguez-Braun, Edith
    Baselga, Jose
    Rosello, Susana
    Sala, Gemma
    Blasco, Inma
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Shinde, Vaishali
    Chakravarty, Arijit
    Bowman, Douglas
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Tabernero, Josep
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (10) : 2844 - 2852
  • [46] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    Dees, E. Claire
    Infante, Jeffrey R.
    Cohen, Roger B.
    O'Neil, Bert H.
    Jones, Suzanne
    von Mehren, Margaret
    Danaee, Hadi
    Lee, Yih
    Ecsedy, Jeffrey
    Manfredi, Mark
    Galvin, Katherine
    Stringer, Bradley
    Liu, Hua
    Eton, Omar
    Fingert, Howard
    Burris, Howard
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 945 - 954
  • [47] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
    E. Claire Dees
    Jeffrey R. Infante
    Roger B. Cohen
    Bert H. O’Neil
    Suzanne Jones
    Margaret von Mehren
    Hadi Danaee
    Yih Lee
    Jeffrey Ecsedy
    Mark Manfredi
    Katherine Galvin
    Bradley Stringer
    Hua Liu
    Omar Eton
    Howard Fingert
    Howard Burris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954
  • [48] Phase I trial with farnesyltransferase inhibitor R115777 in patients (pts) with advanced solid tumors
    Punt, CJA
    Peters, M
    van Maanen, L
    van de Walle, B
    Bol, C
    Willems, L
    Horak, I
    Palmer, P
    Wagener, DJT
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S291 - S291
  • [49] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Delord, Jean-Pierre
    Italiano, Antoine
    Awada, Ahmad
    Aftimos, Philippe
    Houede, Nadine
    Lebbe, Celeste
    Pages, Celine
    Lesimple, Thierry
    Dinulescu, Monica
    Schellens, Jan H. M.
    Leijen, Suzanne
    Rottey, Sylvie
    Kruse, Vibeke
    Kefford, Richard
    Faivre, Sandrine
    Gomez-Roca, Carlos
    Scheuler, Armin
    Massimini, Giorgio
    Raymond, Eric
    TARGETED ONCOLOGY, 2021, 16 (01) : 37 - 46
  • [50] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Jean-Pierre Delord
    Antoine Italiano
    Ahmad Awada
    Philippe Aftimos
    Nadine Houédé
    Céleste Lebbé
    Celine Pages
    Thierry Lesimple
    Monica Dinulescu
    Jan H. M. Schellens
    Suzanne Leijen
    Sylvie Rottey
    Vibeke Kruse
    Richard Kefford
    Sandrine Faivre
    Carlos Gomez-Roca
    Armin Scheuler
    Giorgio Massimini
    Eric Raymond
    Targeted Oncology, 2021, 16 : 37 - 46
12345